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Screening for depression in medical research:
ethical challenges and recommendations
Aisling M Sheehan1 and Hannah McGee2*
Abstract
Background: Due to the important role of depression in major illnesses, screening measures for depression are
commonly used in medical research. The protocol for managing participants with positive screens is unclear and
raises ethical concerns. The aim of this article is to identify and critically discuss the ethical issues that arise when a
positive screen for depression is detected, and offer some guidance on managing these issues.
Discussion: Deciding on whether to report positive screens to healthcare practitioners is both an ethical and a
pragmatic dilemma. Evidence suggests that reporting positive depression screens should only be considered in the
context of collaborative care. Possible adverse effects, such as the impact of false-positive results, potentially
inappropriate labelling, and potentially inappropriate treatment also need to be considered. If possible, the
psychometric properties of the selected screening measure should be determined in the target population, and a
threshold for depression that minimises the rate of false-positive results should be chosen. It should be clearly
communicated to practitioners that screening scores are not diagnostic for depression, and they should be
informed about the diagnostic accuracy of the measure. Research participants need to be made aware of the
consequences of the detection of high scores on screening measures, and to be fully informed about the
implications of the research protocol.
Summary: Further research is needed and the experiences of researchers, participants, and practitioners need to be
collated before the value of reporting positive screens for depression can be ascertained. In developing research
protocols, the ethical challenges highlighted should be considered. Participants must be agreeable to the agreed
protocol and efforts should be made to minimise potentially adverse effects.
Keywords: Depression, Screening, Ethics, Research
Background
An increasing body of evidence has demonstrated the
significant role of depression in major illnesses. A higher
incidence of depression than in the general population
has been found in many patient groups, for example,
type 2 diabetes [1], cancer [2], and Parkinson’s disease
[3]. Approximately one in five patients hospitalised for
myocardial infarction (MI) meet criteria for depression,
which is three times more common than found in com-
munity samples [4]. In addition, meta-analyses have con-
cluded that depression is an independent risk factor for
coronary heart disease, and that patients with depression
are at double the risk of mortality following a MI [4].
Depression is also associated with reduced adherence to
medical treatment or behaviour change recommenda-
tions, and with higher healthcare costs [5].
Mounting evidence on the role of depression across
diseases has resulted in an increased measurement of
depression in research. Standardised, self-rating scree-
ning questionnaires are commonly used, a selection of
which are summarised in Table 1. These screening mea-
sures have acceptable psychometric properties and are
practical to administer [6]. Although they cannot be
used to diagnose depression, high scores indicate a
higher severity of symptoms of depression during a spe-
cific time period (e.g. the past week) [7].
Numerous studies have investigated the optimal cut-off
scores at which depression scores are considered signifi-
cant and are clinically meaningful. A number of statistics
are used to examine the diagnostic accuracy of these cut-
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off scores including sensitivity and specificity. Sensitivity is
the proportion of patients correctly identified as having
depression and specificity is the proportion of patients
correctly identified as not having depression. These scores
vary across studies and according to the characteristics of
the population group for which the measure is validated
[14]. For example, a cut-off score of ≥18 is recommended
for the Beck Depression Inventory-II [13] in primary care
settings, which has been demonstrated to yield a sensiti-
vity of 94% and a specificity of 92% [15], and a score of
≥16 has been recommended in post MI patients, for
which a sensitivity of 88% and a specificity of 92% was
found [16].
Unless the sensitivity and specificity rates are both
100%, the cut-off scores overestimate and underestimate
levels of depression. A lower cut-off score will increase the
sensitivity of the measure and a higher cut-off score will
increase the specificity of the measure, thereby minimising
the number of false-positives, i.e. those incorrectly identi-
fied as depressed. Optimal cut-off scores are generally
higher in populations with a high rate of psychiatric disor-
ders compared to the general population [17].
If participants in a research study screen positive for
depression according to the chosen cut-off score of the
screening measure, the protocol for managing the care of
these participants is unclear. It is not common practice for
researchers to give details on how positive screens identi-
fied within a study are managed. Research Ethics Commit-
tees are beginning to require that a response mechanism
for high depression screening scores be in place before
research can commence. Deciding on a protocol raises a
number of ethical issues. This article considers these
issues and offers recommendations based on the available
evidence and on the practical experience of conducting a
research protocol including depression screening.
Discussion
It is arguable that it may be unethical to ignore potential
depression. Depression as a risk factor for mortality has
been shown to be comparable in strength to smoking
[18]. The Global Burden of Disease (GBD) study quan-
tifies the health effects of more than 100 diseases and
injuries and found that in 2004, unipolar depression was
the leading cause of disability in middle- and high-
income countries [19]. Participants with positive screens
for depression could potentially be referred for a more
comprehensive evaluation by a professional qualified in
diagnosing and managing depression. Guidelines pro-
vided by the American Heart Association (AHA) [20],
the U.S. Preventive Services Task Force (USPSTF) [21],
and the National Institute for Health and Clinical Exce-
llence (NICE) [22] all recommend this protocol. The
challenge is that this places a high demand on mental
health services and their treatment capacity [23].
An alternative would be to refer participants to pri-
mary care where depression is most commonly mana-
ged. However, research suggests that the treatment of
depression in primary care is inadequate. Resources are
limited in primary care and access to psychological
interventions is often not available. Hence, antidepre-
ssants are the most commonly prescribed treatment, but
are often not patients’ preferred choice of treatment
[24]. An estimated 20-30% of those identified as de-
pressed in primary care settings receive adequate care
and follow-up, and the majority of patients prescribed
antidepressants discontinue them soon after initiation
[25]. Three systematic reviews [26-28] on the evidence
for screening for depression in primary care settings
concluded that reporting screening results to primary
care practitioners can improve depressive symptoms
when there is additional staff providing depression care
support. Benefit was not found in the absence of colla-
borative care or system improvements or supports, such
as clinician training, provision of patient educatio-
nal material, support staff, follow-up visits, and mental
health referrals.
The most appropriate approach when research partici-
pants screen positive for depression appears to be the
reporting of positive depression screens in the context of
collaborative care. This involves the collaboration be-
tween medical and mental health specialists for optimal
disease management [29], and helps to improve diagnostic
accuracy and the quality of care [30]. The USPSTF [21]
recommends that clinical settings in which screening for
Table 1 Summary of commonly used depression screening measures
Measure Items Scale Range Recall period Time to complete
PHQ9 [8] 9 4-point 0-27 Last 2 weeks < 3 minutes
CES-D [9] 20 4-point 0-60 Past week 10 minutes
GDS-15 [10] 15 Yes or no 0-15 Past week 2-5 minutes
SCL-90-D [11] 16 5-point 16-80 Past 7 days < 5 minutes
HADS-D [12] 7 4-point 0-21 Past 7 days < 3 minutes
BDI-II [13] 21 4-point 0-63 Last 2 weeks 5-10 minutes
Abbreviations: BDI-II, Beck Depression Inventory-II; CES-D, Center for Epidemiological Studies Depression Scale; GDS, Geriatric Depression Scale; HADS-D, Hospital
Anxiety and Depression Scale, depression subscale; PHQ-9, Patient Health Questionnaire-9; SCL-90-D, depression subscale of the Symptom Checklist 90.
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depression occurs should have systems in place for accu-
rate diagnosis, effective treatment, and follow-up for de-
pression. However, information on the care available to
research participants is not always readily available. This
challenge is particularly pertinent for research conducted
across multiple sites. Other ethical challenges also need to
be considered before the decision is made to report posi-
tive screens. There are a number of possible adverse
effects including false-positive results, inappropriate label-
ling, and inappropriate treatment. In addition, reporting
positive screens has implications for confidentiality and
informed consent.
Reaching thresholds for depression on screening mea-
sures does not guarantee meeting the criteria for a diagno-
sis of depression. It is estimated that 59% of patients
screening positive for depression are incorrectly identified
as depressed, i.e. they have false-positive results [25]. The
psychometric properties of the chosen screening measure
therefore need to be carefully considered. These proper-
ties have been demonstrated to vary according to patient
group, gender, age, and type of depression [31]. Ideally,
evidence on the levels of sensitivity and specificity for the
screening measure in the target population of the research
should be examined, so that appropriate cut-off scores for
that population can be chosen. Choosing a cut-off score
with low specificity poses the danger of research partici-
pants being inappropriately labelled as depressed and
subsequently receiving inappropriate treatment. A high
specificity of 95% or more is therefore recommended. This
would mean that 1 in 20 positive screens would be false-
positives. However, information on the diagnostic accu-
racy of screening measures in particular populations is not
always readily available. Further research on optimal cut-
off scores is therefore needed.
Research is also needed on the psychological impact of
receiving false-positive results for depression. Although
this has not been examined for depression screening
[27], receiving false-positive results has been shown to
cause psychological distress and negatively impact upon
health behaviour for other screening programmes, such
as mammography screening [32]. In order to minimise
any potential harm when referring positive screens, it
should be clearly communicated to both participants
and medical professionals that high screening scores are
not diagnostic for depression, and information on the
diagnostic accuracy of the screening measure should be
provided. They should be made aware about the possible
transient nature of depressive symptoms and the risk of
being incorrectly labelled as depressed. Inappropriate
treatment based on an inappropriate label is also po-
ssible if further diagnostic testing is not conducted. A
position statement of the American College of Preven-
tive Medicine [33] states that “[w]ithout proper follow-
up, false-positive scores can lead to harmful labelling,
unnecessary additional testing, and inappropriate treat-
ment”. The duration of symptoms, the degree of impair-
ment, and co-morbid physical and psychiatric disorders
all need to be evaluated before deciding on appropriate
treatment [7].
Issues of informed consent and confidentiality also need
to be considered. If positive screens will be referred to
medical practitioners, participants should be aware of and
agreeable to this referral process, according to ethical prin-
ciples [34]. The participant information leaflet and consent
form should highlight this information clearly. Partici-
pants’ depression screening results should be confidential,
yet they need to be informed that results will be disclosed
to their medical team in the event of a positive screen.
They should be aware of which members of their medical
team will have access to this information and have the
right not to consent to this information being disclosed.
Summary
The debate on the value of reporting positive screens for
depression in research participants to medical practi-
tioners is unresolved. Ethically, it is increasingly difficult
to ignore high scores on screening measures. However,
it is important that the protocol response results in
improved outcomes for patients. The most evidence-
based approach appears to be the reporting of positive
screens in the context of collaborative care. There is cu-
rrently no evidence to warrant the referral of positive
screens in the absence of collaborative care settings.
Researchers therefore need to be aware of the care struc-
tures available to participants. This is more challenging
to determine in large-scale, multi-centre studies. Poten-
tial adverse effects and issues of confidentiality and
informed consent also need to be reflected on when
considering the referral of positive screens to medical
practitioners.
Evidence on the psychometric properties for the
screening measure in the target population should be
ascertained, where possible. The diagnostic accuracy of
the measure should be clearly reported to medical prac-
titioners to whom participants are referred. The non-
diagnostic nature of the measure should be emphasised.
Participants should also be made aware of the potential
for false-positives, and the possible transient nature of
their depressive symptoms. Prior to recruitment, all par-
ticipants need to be agreeable to the referral protocol for
positive depression screens. Further research is needed
to examine the potential adverse effects of referring
positive screens, including the psychological impact of
receiving false-positive results and potentially inappro-
priate treatment. The experiences of other researchers
need to be collated so that the potential challenges of
referring patients, as discussed here, can be anticipated
and resolved. In the meantime, every effort should be
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made to ensure that the potentially adverse effects of re-
ferring positive depression screens in research protocols
are minimised.
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